Amyvid, Intravenous Solution — Competitive Intelligence Brief

Amyvid, Intravenous Solution (Amyvid, Intravenous Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PET imaging agent. Area: Neurology.

phase 2 PET imaging agent beta-amyloid plaques Neurology Small molecule

Target snapshot

Amyvid, Intravenous Solution (Amyvid, Intravenous Solution) — Universidad Central del Caribe. Amyvid is a positron emission tomography (PET) imaging agent that binds to beta-amyloid plaques in the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amyvid, Intravenous Solution TARGET	Amyvid, Intravenous Solution	Universidad Central del Caribe	phase 2	PET imaging agent	beta-amyloid plaques
Flotufolastat (18F)	Flotufolastat (18F)	Blue Earth Diagnostics	marketed	Folate receptor-targeted PET imaging agent	Folate receptor alpha (FR-α)
[Ga-68]PSMA	[Ga-68]PSMA	Norbert Avril, M.D.	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
piflufolastat (18F)	piflufolastat (18F)	Blue Earth Diagnostics	marketed	PSMA-targeting PET imaging agent	PSMA (prostate-specific membrane antigen)
[18F]Florbetapir PET imaging	[18F]Florbetapir PET imaging	Institute for Neurodegenerative Disorders	marketed	PET imaging agent	Amyloid-beta (Aβ) fibrils
Neuraceq (florbetaben 18F)	Neuraceq (florbetaben 18F)	Piramal Imaging Limited	marketed	PET imaging agent	Amyloid-beta plaques
[11C]raclopride	[11C]raclopride	New York State Psychiatric Institute	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PET imaging agent class)

1. University of California, San Francisco · 2 drugs in this class
2. Central Hospital, Nancy, France · 1 drug in this class
3. Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
4. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
5. Institute for Neurodegenerative Disorders · 1 drug in this class
6. OHSU Knight Cancer Institute · 1 drug in this class
7. Piramal Imaging Limited · 1 drug in this class
8. SOFIE · 1 drug in this class
9. Universidad Central del Caribe · 1 drug in this class
10. University of California, Irvine · 1 drug in this class